Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 25 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2018 to 1 Mar 2019.
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.